Apalutamide
Apalutamide is a small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018.